• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Cipher Announces Sale of American Assets

    Bryan Mc Govern
    May. 01, 2017 08:36AM PST
    Pharmaceutical Investing

    Cipher Pharmaceuticals completes sale of assets from Cipher US to EPI Group.

    Cipher Pharmaceuticals (TSX: CPH) will sell all assets from its US subsidiary to EPI Group.
    As quoted in the press release:

    Under the terms of the Agreement, EPI acquired substantially all the assets of Cipher US for cash consideration of US$13.6 million, subject to certain purchase price adjustments and the transfer of certain liabilities, plus a regulatory milestone of US$0.75 million if certain predefined conditions are achieved.
    This transaction does not include or impact Cipher’s licensing business in the U.S.
    “The sale of our Cipher US assets is consistent with our stated strategy to focus our resources on the continued expansion of our Canadian commercial operation, our highly profitable global licensing business and our pipeline,” said Robert Tessarolo, President and Chief Executive Officer of Cipher. “I would like to thank Stephen Lemieux, our Chief Financial Officer, for his leadership in negotiating and executing this transaction. We offer our sincere appreciation to the U.S. team for their commitment and dedication during their time with Cipher.”

    Click here to read the full press release.

    pharmaceutical investingcipher pharmaceuticals
    The Conversation (0)

    Go Deeper

    AI Powered
    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Syntheia Signs Non-Binding LOI for Call Center Acquisition

    Syntheia Signs Non-Binding LOI for Call Center Acquisition

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×